文献速递内脏/肾动脉与血管畸形

逆行肠系膜旁路术治疗慢性肠系膜缺血的长期通畅率与临床结局

Long-Term Patency and Clinical Outcomes After Retrograde Mesenteric Bypass for Chronic Mesenteric Ischemia.
PubMed 文献 · Ann Vasc Surg · 2026-10-28

本研究评估34例2009至2024年接受逆行肠系膜旁路术的慢性肠系膜缺血患者的长期移植物通畅率和临床结局。中位随访约7.5年,1年、3年、5年、10年一期通畅率分别为93.3%、93.3%、89.4%、85.0%,围术期存活者症状均缓解且无复发,无患者需再干预。结论认为该术式长期通畅稳定、症状缓解持久、围术期死亡率低,是内膜血管重建不可行时的耐久开放手术选择。

要点

  • 逆行肠系膜旁路术后10年一期通畅率达85.0%,无早期血栓形成。
  • 围术期存活者症状全部缓解,随访期间无复发症状。
  • 无患者需要再干预,围术期死亡率低。

核心结论

  • 逆行肠系膜旁路术与稳定的长期通畅率、持久的症状缓解和低围术期死亡率相关。
  • 该术式仍是慢性肠系膜缺血的耐久开放手术选择,尤其适用于内膜血管重建不可行或难以获得持久效果时。

研究设计与样本

  • 回顾性评估2009至2024年间34例因慢性肠系膜缺血接受逆行肠系膜旁路术的患者。
  • 采用Kaplan-Meier分析计算通畅率,血栓形成分为早期(≤30天)、中期(31-365天)和晚期(>365天)。

主要发现

  • 肠系膜上动脉旁路术33例(97.1%),腹腔干旁路术25例(73.5%),双血管重建24例(70.6%)。
  • 中位随访2737天(IQR 1760-4353),约7.5年。
  • 无早期血栓形成,观察到2例中期闭塞和3例晚期闭塞。
  • 1年和3年一期通畅率均为93.3%,5年为89.4%,10年为85.0%。
  • 围术期存活者血运重建后症状均缓解,随访期间无复发症状记录,无患者需再干预。

关键数值与推荐

  • 1年、3年、5年、10年一期通畅率分别为93.3%、93.3%、89.4%、85.0%。
  • 血栓形成分类:早期≤30天,中期31-365天,晚期>365天。

临床怎么用

  • 对于慢性肠系膜缺血患者,当内膜血管重建不可行或预期难以持久时,可考虑逆行肠系膜旁路术。
  • 术后长期随访中需关注中期和晚期移植物闭塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Chronic mesenteric ischemia (CMI) is an uncommon yet clinically significant condition resulting from insufficient blood flow to the gastrointestinal tract, frequently leading to severe symptoms and increased morbidity. Although endovascular therapy has become the initial treatment strategy in many centres, open surgical reconstruction remains an important option for selected patients. This study evaluated long-term graft patency and clinical outcomes after retrograde mesenteric bypass. METHODS: We evaluated 34 patients treated with retrograde mesenteric bypass for CMI between 2009 and 2024. Patency rates were measured with Kaplan-Meier analysis. Thrombosis was classified as early (≤30 days), mid-term (31-365 days), or late (>365 days). RESULTS: Superior mesenteric artery bypass was performed in 33 patients (97.1%), celiac bypass in 25 (73.5%), and dual-vessel reconstruction in 24 (70.6%). Median follow-up was 2737 days (IQR, 1760-4353), approximately 7.5 years. No early thrombosis occurred. Two mid-term and three late occlusions were observed. Primary patency rates were 93.3% at 1 and 3 years, 89.4% at 5 years, and 85.0% at 10 years. Clinical symptoms resolved after revascularisation in all patients surviving the perioperative period, and no recurrent symptoms were documented during follow-up. No patient required reintervention. CONCLUSIONS: Retrograde mesenteric bypass was associated with stable long-term patency, sustained symptom resolution, and low perioperative mortality. It remains a durable open surgical option for chronic mesenteric ischemia, particularly when endovascular revascularisation is not feasible or is unlikely to provide durable results.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Sezen A, Kapkin AY, Oguz E, et al. Long-Term Patency and Clinical Outcomes After Retrograde Mesenteric Bypass for Chronic Mesenteric Ischemia. Ann Vasc Surg. 2026. PMID: 42951186. doi:10.1016/j.avsg.2026.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。